Genentech and Parvus develop autoimmune therapies in collaboration

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/portokalis)
(Image: Getty/portokalis)

Related tags: Genentech, Autoimmune, Autoimmune disease, Collaboration, Manufacturing, Commercialization, Precision medicine

Genentech will collaborate with biopharma company Parvus to manufacture and commercialize Navacim therapeutics for the treatment of autoimmune disease.

Parvus, a biopharmaceutical company focused on developing disease-specific immunoregulatory medicines to treat autoimmune diseases that maintain normal immunity, will work with Genentech in this collaboration.

Together, the companies will collaborate to develop, manufacture, and commercialize Navacim therapies for inflammatory bowel disease, autoimmune liver disease, and celiac disease.

A spokesperson for Parvus told us that its Navacim platform can generate therapeutic candidates that may be able to treat, and possibly reverse, a wide range of autoimmune diseases ‘without dampening’ the immune system.

“Navacims are precision medicines designed to trigger a naturally occurring immunoregulatory mechanism of the mammalian immune system that has evolved to protect against autoimmune disease. Navacim activity depends on the presence of disease-causing, autoimmune T cells,”​ the spokesperson told us.

The spokesperson added that this collaboration is beneficial as it “cannot develop all [its] assets alone,” ​and will provide the company with funding to expand its portfolio of Navacim drug candidates on its own at a later date.

Genentech, a member of the Roche group, eligible to receive research, development, and commercialization milestone payments totally up to $800m (€716m). Parvus is also eligible to receive certain milestone payments in other disease areas.

Parvus will conduct pre-clinical and clinical development activities through Phase I. Genentech will be responsible for development from Phase II on, including regulatory submissions and commercialization.

Related news

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us


View more